Traders should monitor for upcoming topline efficacy data from the third cohort, which could serve as a near-term catalyst. While safety progression is positive, lack of efficacy data limits upside potential; any future delays or adverse findings could negatively impact the micro-cap stock.
Price Chart
Executive Summary
Clearmind Medicine announced the continuation of participant enrollment in the third cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic drug candidate for Alcohol Use Disorder (AUD), following positive safety and tolerability results from earlier cohorts. The trial is ongoing at major institutions including Yale and Johns Hopkins, with the Data and Safety Monitoring Board unanimously approving progression.
Key Facts
- Clearmind Medicine is advancing to the third cohort of its Phase I/IIa clinical trial for CMND-100 in Alcohol Use Disorder (AUD).
- The Data and Safety Monitoring Board (DSMB) reviewed data and approved continuation based on safety and tolerability from prior cohorts.
- Trial sites include Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center.
- CMND-100 is a non-hallucinogenic, oral MEAI-based neuroplastogen compound.
- No efficacy data or financial results were disclosed; announcement is operational in nature.
Financial Impact
No immediate financial impact disclosed — trial progression is a developmental milestone without quantified revenue or cost implications.
Risk Factors
- Clinical trial may fail to show efficacy despite safety success.
- As a micro-cap biotech with no revenue, Clearmind remains highly dependent on future financing, which could lead to significant dilution.
- Forward-looking statements carry high uncertainty; no assurance of regulatory approval or commercial viability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253850 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $6.10 | awaiting T+60 | — | $5.97 (−2.10%) |
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.97 (+0.79%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.97 (−8.20%) |
Oct 16, 2026 11d ago | 6-K | $6.00 | awaiting T+60 | — | $5.97 (+0.55%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.97 (−4.22%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.97 (+602.00%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.97 (+602.00%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.97 (−13.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers